Generic Zantac Plaintiffs Say Cost Information Not Confidential

Generic antacid makers that were dismissed from federal multidistrict litigation alleging the drugs caused cancer and are now planning to seek to impose costs on the plaintiffs have failed to justify their request to file certain supporting materials under seal, the plaintiffs told the MDL court.

The court in July dismissed Apotex Inc. and other makers of generic versions of Zantac, which the companies say makes them prevailing parties and raises the presumption that they are entitled to an award of litigation costs.

Apotex and other companies said they intend to submit bills of costs with supporting evidence and invoices, ...